Ironwood Pharmaceuticals, Inc. - (IRWD): Price and Financial Metrics


Ironwood Pharmaceuticals, Inc. - (IRWD): $11.53

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

IRWD POWR Grades


  • IRWD scores best on the Value dimension, with a Value rank ahead of 98.14% of US stocks.
  • The strongest trend for IRWD is in Growth, which has been heading down over the past 179 days.
  • IRWD's current lowest rank is in the Momentum metric (where it is better than 12.28% of US stocks).

IRWD Stock Summary

  • With a one year PEG ratio of 5.74, Ironwood Pharmaceuticals Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than just 23.16% of US stocks.
  • With a price/earnings ratio of 3.88, Ironwood Pharmaceuticals Inc P/E ratio is greater than that of about only 3.56% of stocks in our set with positive earnings.
  • Over the past twelve months, IRWD has reported earnings growth of 67.56%, putting it ahead of 73.3% of US stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Ironwood Pharmaceuticals Inc are PGEN, GKOS, KN, TMDX, and AFIB.
  • IRWD's SEC filings can be seen here. And to visit Ironwood Pharmaceuticals Inc's official web site, go to www.ironwoodpharma.com.

IRWD Valuation Summary

  • In comparison to the median Healthcare stock, IRWD's price/sales ratio is 36.84% higher, now standing at 5.2.
  • Over the past 141 months, IRWD's EV/EBIT ratio has gone up 24.6.
  • Over the past 141 months, IRWD's EV/EBIT ratio has gone up 24.6.

Below are key valuation metrics over time for IRWD.

Stock Date P/S P/B P/E EV/EBIT
IRWD 2021-08-31 5.2 4.2 4.2 10.3
IRWD 2021-08-30 5.2 4.2 4.3 10.4
IRWD 2021-08-27 5.2 4.2 4.2 10.4
IRWD 2021-08-26 5.2 4.2 4.2 10.3
IRWD 2021-08-25 5.2 4.2 4.2 10.3
IRWD 2021-08-24 5.2 4.2 4.2 10.4

IRWD Growth Metrics

    Its year over year cash and equivalents growth rate is now at 89.42%.
  • Its 3 year revenue growth rate is now at 85.47%.
  • Its 3 year net cashflow from operations growth rate is now at -16.06%.
Over the past 34 months, IRWD's revenue has gone up $67,539,000.

The table below shows IRWD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 413.753 261.895 528.448
2021-09-30 413.303 248.84 530.278
2021-06-30 413.024 227.407 508.856
2021-03-31 398.425 198.927 142.757
2020-12-31 389.523 168.836 106.176
2020-09-30 399.144 144.903 110.83

IRWD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • IRWD has a Quality Grade of B, ranking ahead of 94.53% of graded US stocks.
  • IRWD's asset turnover comes in at 0.622 -- ranking 50th of 682 Pharmaceutical Products stocks.
  • LGND, COLL, and OMER are the stocks whose asset turnover ratios are most correlated with IRWD.

The table below shows IRWD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.622 0.998 0.305
2021-03-31 0.761 0.998 0.286
2020-12-31 0.820 0.992 0.226
2020-09-30 0.916 0.967 0.230
2020-06-30 1.077 0.976 0.213
2020-03-31 1.207 0.951 0.198

IRWD Price Target

For more insight on analysts targets of IRWD, see our IRWD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $13.83 Average Broker Recommendation 1.71 (Moderate Buy)

IRWD Stock Price Chart Interactive Chart >

Price chart for IRWD

IRWD Price/Volume Stats

Current price $11.53 52-week high $14.27
Prev. close $11.53 52-week low $10.13
Day low $11.21 Volume 2,484,500
Day high $11.58 Avg. volume 2,985,375
50-day MA $11.63 Dividend yield N/A
200-day MA $11.90 Market Cap 1.77B

Ironwood Pharmaceuticals, Inc. - (IRWD) Company Bio


Ironwood Pharmaceuticals engages in the research, development, and commercialization of human therapeutic products, with a key focus being the treatment of adult men and women suffering from irritable bowel syndrome. The company was founded in 1998 and is based in Cambridge, Massachusetts.


IRWD Latest News Stream


Event/Time News Detail
Loading, please wait...

IRWD Latest Social Stream


Loading social stream, please wait...

View Full IRWD Social Stream

Latest IRWD News From Around the Web

Below are the latest news stories about Ironwood Pharmaceuticals Inc that investors may wish to consider to help them evaluate IRWD as an investment opportunity.

Ironwood (IRWD) Q4 Earnings Miss, Linzess Volume Grows

Ironwood (IRWD) witnesses flat year-over-year sales growth. Its fourth-quarter earnings miss estimates. The company maintains revenue guidance for 2022. Stock declines.

Yahoo | February 18, 2022

Ironwood Pharmaceuticals, Inc. (IRWD) CEO Thomas McCourt on Q4 2021 Results - Earnings Call Transcript

Ironwood Pharmaceuticals, Inc. (IRWD) Q4 2021 Earnings Conference Call February 17, 2022 08:30 A.M. ET Company Participants Matt Roache - Director of IR Thomas McCourt - CEO Michael Shetzline - CMO and Head of R&D Sravan K. Emany - CFO Conference Call Participants Boris Peaker - Cowen & Company Eric...

SA Transcripts on Seeking Alpha | February 17, 2022

Ironwood Pharmaceuticals Non-GAAP EPS of $0.27 misses by $0.07, revenue of $117.13M beats by $6.96M

Ironwood Pharmaceuticals press release (IRWD): Q4 Non-GAAP EPS of $0.27 misses by $0.07.Revenue of $117.13M (+0.4% Y/Y) beats by $6.96M.Guidance: FY22 The company expects the…

Seeking Alpha | February 17, 2022

Ironwood Reports Mixed Q4 Results; Linzess Joins Blockbuster Club As US Sales Exceed $1B

Ironwood Pharmaceuticals Inc (NASDAQ: IRWD ) reported Q4 FY21 sales of $117.1 million , compared to $116.7 million in Q4 FY20, beating the consensus of $109.87 million. Ironwood recorded $113.7 million in collaboration revenue in Q4 related to sales of LINZESS in the U.S., a 2.7% Y/Y increase, and $3.4 million in royalties and other revenue. Total … Full story available on Benzinga.com

Benzinga | February 17, 2022

Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; LINZESS® (linaclotide) Achieves Blockbuster Status as U.S. Net Sales Exceed $1 Billion in 2021

BOSTON, February 17, 2022--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its fourth quarter and full year 2021 results.

Yahoo | February 17, 2022

Read More 'IRWD' Stories Here

IRWD Price Returns

1-mo 2.22%
3-mo -8.85%
6-mo -1.71%
1-year -8.35%
3-year 7.26%
5-year -39.25%
YTD -1.11%
2021 2.37%
2020 -14.43%
2019 28.47%
2018 -30.89%
2017 -1.96%

Continue Researching IRWD

Here are a few links from around the web to help you further your research on Ironwood Pharmaceuticals Inc's stock as an investment opportunity:

Ironwood Pharmaceuticals Inc (IRWD) Stock Price | Nasdaq
Ironwood Pharmaceuticals Inc (IRWD) Stock Quote, History and News - Yahoo Finance
Ironwood Pharmaceuticals Inc (IRWD) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6156 seconds.